{"id":"methargen","rwe":[],"tags":[{"label":"methargen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"viacutan","offLabel":[],"synonyms":["silver dinaphthylmethanedisulphonate","methargen","viacutan","methylenedinaphthalenesulfonic acid disilver salt"],"timeline":[],"approvals":[],"brandName":"Viacutan","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"methargen","explanation":"Imagine your body's cells have locks on them, and the key to unlocking the right response is a specific molecule. Viacutan is designed to fit into this lock, allowing the cell to respond in a way that treats a particular condition. However, the exact lock and key mechanism of Viacutan is not yet understood.","oneSentence":"Viacutan works by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"The technical details of Viacutan's mechanism of action are not available, as its target and pharmacological properties are unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3774","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=methargen","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:21:42.576424","biosimilars":[],"competitors":[],"genericName":"methargen","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"D7W929228C","PUBCHEM_CID":"35723"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Viacutan, also known as methargen, is a small molecule drug of the methargen class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Viacutan is unclear, with no information available on its patent status, generic manufacturers, or off-patent status. Further research is needed to determine the safety and efficacy of this drug. As a result, Viacutan is not currently a viable treatment option.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}